KR100996577B1 - Lactobacillus curvatus HY7601 having inhibitory activity against blood cholestrol and obesity, and product containing thereof as an effective factor - Google Patents

Abstract

The present invention provides a novel Lactobacillus curvatus HY7601 having an effect of inhibiting obesity and lowering cholesterol in the blood by increasing intracellular inflow of cholesterol through an increase in LDL-receptor and as an active ingredient. Containing pharmaceutical compositions, fermented milk, beverages, and functional foods containing, the novel Lactobacillus curvatus HY7601 according to the present invention, as well as reducing the amount of cholesterol and triglycerides in the blood as well as inhibiting obesity Since it is very excellent, it is possible to provide a functional food and pharmaceutical composition that affects lipid metabolism using Lactobacillus curvatus HY7601.

Cholesterol, Lactobacillus curvatus, low density lipoprotein receptor (LDL-receptor), SREBP-2

Description

Novel Lactobacillus curvatus HY7601 having inhibitory activity against blood cholestrol and obesity, and product containing describes as an effective factor

The present invention relates to a novel Lactobacillus curvatus HY7601 having a blood cholesterol lowering effect and an obesity inhibitory effect, and a pharmaceutical composition containing the same as an active ingredient, fermented milk, beverages, and health functional foods. A novel Lactobacillus curvatus HY7601 with the effect of lowering the amount of cholesterol in the blood by increasing intracellular intake of cholesterol through increasing LDL-receptor and the effect of inhibiting obesity. It relates to a pharmaceutical composition, fermented milk, beverages, health functional foods containing as an ingredient.

As a result of the recent increase in blood cholesterol levels in Koreans, the incidence of diseases such as cerebrovascular disorders, heart disease, and high blood pressure is also increasing every year. This change may be attributable to changes in the diet of Koreans with a significant increase in animal fat and protein intake.

Most of the cholesterol in the blood is in the form of low-density lipoprotein (LDL), and it is introduced into the cell through the low-density lipoprotein receptor (LDL-receptor) of the cell membrane. Is moved. High concentrations of intracellular cholesterol decrease the synthesis rate of LDL-receptor and slow down the absorption of cholesterol from the blood into the cell, resulting in the accumulation of blood cholesterol.

Currently, niacin, cholestyramine, and statins are widely used as drugs to lower blood cholesterol levels. Niacin acts to inhibit the secretion of very low-density lipoproteins in the liver, and bile acid sequestrants such as cholestyramine prevent cholesterol from being reabsorbed into the liver, which naturally leads to bile acid biosynthesis. To increase the consumption. Compactin derivatives, lovastatin, lovastatin, pravastatin, and simvastatin, have the highest market share and are HMG-CoA reductase (3-hydroxy-methyl), a cholesterol biosynthesis regulator. -glutaryl coenzyme A reductase) inhibits the activity. As a result, the amount of LDL-receptor is increased and the amount of cholesterol in the blood decreases as the influx of LDL increases. In addition, cholesterol ester transfer protein (CETP), an enzyme that inhibits the activity of cholesterol transfer enzyme acyl-CoA: cholesterol acyltransferase (ACAT) or transfers cholesterol in high-density lipoprotein to LDL, Attempts have been made to suppress blood cholesterol, including inhibition.

However, since these drugs have side effects such as hepatotoxicity, gastrointestinal disorder, and carcinogenicity, diet therapy that limits the intake of lipids to an appropriate range is more important than drug therapy. However, since dietary restrictions also entail mental pain and deprivation of the enjoyment of eating, strict enforcement is difficult and often has limitations.

On the other hand, many efforts have been made to reduce blood cholesterol levels using lactic acid bacteria, which have been considered safe microorganisms. Lactobacillus has been reported to show the effects of maintaining normal intestinal flora, improving intestinal flora, antidiabetic and antihyperlipidemic effects, inhibiting carcinogenesis, inhibiting colitis, and nonspecific activity of the host's immune system. Among them, the strain Lactobacillus is a major member of the normal microbial community in the intestine of the human body, which has long been known to be important in maintaining a healthy digestive system and the vaginal environment, and the US Public Health Service guidelines. ), All of the Lactobacillus strains currently deposited with the American Strain Deposit Agency (ATCC) are classified as 'Bio-safty Level 1', which is not known for any potential risk of causing disease in humans or animals. .

The well known cholesterol lowering mechanism of Lactobacillus strains is the same as that of cholestyramine. That is, the discharged bile acid is not desorbed into the liver as a result of deconjugation by the Lactobacillus strain, resulting in increased consumption of cholesterol, a bile acid biosynthetic raw material, and naturally reduced amount of cholesterol. However, other mechanisms are still unknown.

Accordingly, the present inventors completed the present invention by confirming the fact that the LDL-receptor expression of the cell membrane is increased by Lactobacillus curvatus and the cholesterol inflow is ultimately decreased and the inhibition of obesity is increased as Lactobacillus curvatus is increased. Was done.

Accordingly, an object of the present invention is to provide a novel Lactobacillus curvatus ( Lactobacillus curvatus ) and a pharmaceutical composition containing the same as an active ingredient, fermented milk, beverages, health functional foods having a blood cholesterol lowering and obesity inhibitory effect .

In order to achieve the above object, the present invention provides a novel Lactobacillus curvatus HY7601 which has an effect of inhibiting obesity while lowering blood cholesterol level by increasing LDL-receptor expression level and intracellular cholesterol influx of cell membranes. It is characterized by providing.

Hereinafter, the present invention will be described in detail.

In order to isolate the strain according to the present invention, kimchi prepared in domestic homes in a liquid medium containing MRS (MRS) containing 0.02% sodium azide (MRS) incubated for 24 hours at 37 ℃, 10μl platinum The culture medium was taken using and smeared again on MLS agar plate medium containing 0.02% sodium azide and incubated for 48 hours at 37%. The strain of the present invention was isolated by testing the activity of Sterol regulatory element-binding protein 2 (hereinafter referred to as 'SREBP-2') among the fungi thus formed.

In other words, SREBP-2, a transcription factor of lipid metabolism-related genes (HMGCR, LDL-receptor, etc.), is an important gene that contributes to intracellular cholesterol homeostasis. As the expression level of LDL-receptor, a subordinate gene of SREBP-2, also increased, cholesterol in the blood flowed into the cells, reducing the amount of cholesterol in the blood. Strains with activity that increase the activity of SREBP-2 in cells were isolated.

Observation of the isolated strains was incubated for 48 hours at 37 ℃ in MRS agar plate medium and the size and shape of the isolated strains were observed by light microscopy (SAMWON, CSB-FEI) through Gram staining (Cowan, 1974). The biochemical characteristics of a strain were classified and identified according to Bergey's Manual of Systematic Bacteriology and Bergey's Manual of Determinative Bacteriology after the characteristics of the strains were investigated according to the methods of Cowan, Steel (1984) and Macfaddin (1984). Catalase test was used to observe the presence of oxygen after adding 3% hydrogen peroxide. Oxidase test was carried out by adding 1% dimethyl-p-phenylenediamine gydrochloride to observe discoloration.

Therefore, the characteristics of the novel lactic acid bacteria according to the present invention are as follows.

1) Form of bacteria

Characteristics of Bacteria When incubated in MRS Agar Plate Medium at 37 ° C for 2 Days

① Cell Type: Bacillus

② Mobility: None

③ Sporulation ability: None

④Gram staining: positive

2) Form of the collapse

Form of fungi when incubated for 2 days at 37 ° C on MRS agar plate medium

① Shape: Round

② bump: convex

③ Surface: Smooth

3) physiological properties

① Growth temperature: Growth possible Growth temperature: 15 ~ 40 ℃

Optimum growth temperature: 36 ~ 38 ℃

② Growth pH: Growth possible Growth pH: 5.0 ~ 7.5

Optimum pH: 6.0-6.5

③ Effects on oxygen: anaerobic anaerobic

Catalase:-

5) Whether gas is formed:-

6) Growth at 15 ℃: +

7) Growth at 45 ℃:-

8) Indole Production:-

9) lactic acid production: +

10) sugar fermentation experiment and identification

The results of the sugar fermentation experiment using the api 50 CH kit of Biomerieux are shown in Table 1 and FIG. 1.

Based on the morphological, physiological and growth characteristics of the above bacteria, the strain of the present invention was identified as Lactobacillus curvatus ( Lactobacillus curvatus ), the inventors named it Lactobacillus curvatus ( HYacte ) HY7601, As of January 22, 2009, the fund was deposited with the Korea Biotechnology Research Institute (Accession No .: KCTC 11456BP).

Meanwhile, the pharmaceutical composition for inhibiting blood cholesterol drop and obesity, which contains a novel Lactobacillus catheterus HY7601 having an effect of inhibiting blood cholesterol drop and obesity of the present invention as an active ingredient, is used alone or in combination with excipients used pharmaceutically. It may be used by formulating the formulation in the form of tablets, capsules and the like according to the method commonly used pharmaceutically.

For humans, typical daily dosages can range from 1-30 mg / kg body weight, and can be administered once or in divided doses. However, the actual dosage should be determined in light of several relevant factors such as the route of administration, age, sex, weight, health status and severity of the disease.

Of course, the pharmaceutical composition of the present invention is a drug that can be used with confidence even when taken for a long time because there is little toxicity and side effects.

In addition, the fermented milk containing a novel Lactobacillus cabbetts HY7601 having an effect of lowering blood cholesterol and anti-obesity as an active ingredient is homogenized at 150 bar by combining a lactobacillus culture solution, Lactobacillus cabbetts HY7601 and mixed fruit syrup in a constant ratio. After cooling to 10 ℃ or less and then packaged in a container to prepare.

In addition, the beverage containing the novel Lactobacillus cabbetts HY7601 as an active ingredient having blood cholesterol lowering and obesity inhibitory effect was homogenized at 150 bar by combining a mixed juice syrup, Lactobacillus cabbetts HY7601 and water at a constant ratio. After cooling to 10 ° C. or less, the product is packaged in a small packaging container such as a glass bottle or a plastic bottle.

In addition, a health functional food containing a novel Lactobacillus corbetts HY7601 having an effect of lowering blood cholesterol and obesity as an active ingredient includes vitamins B1, B2, B5, B6, E and acetic acid esters, nicotinic acid amides, oligosaccharides and the like may be added and other food additives may be added.

As described above, Lactobacillus curvatus HY7601 according to the present invention reduces the amount of cholesterol and triglycerides in the blood, as well as excellent anti-obesity effect, so Lactobacillus curvatus ( Lactobacillus curvatus ) HY7601 It can be used as a functional food and pharmaceutical composition affecting the lipid metabolism using.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are not intended to limit the scope of the present invention, and ordinary changes by those skilled in the art are possible within the scope of the technical idea of the present invention.

≪ Example 1 >

Preparation of lyophilized powders, including Lactobacillus cavities HY7601

The lactobacillus corbettus HY7601 of the present invention is a liquid medium containing Proteose peptone # 3 for food ingredients, Yeast Extract, Beef Extract, and glucose, incubated at 37 ° C. for about 16 hours, and then centrifuged and sterilized. It was washed with physiological saline and then dispersed in sterile oil. Freeze-drying again yielded about 10 ¹¹ cfu bacteria per gram (g) of lyophilized powder. This lyophilized powder was used as a blood cholesterol lowering material.

Meanwhile, the Lactobacillus corpus HY7601 of the present invention may be provided in the form of a lyophilized powder or culture.

<Example 2>

Preparation of a pharmaceutical composition containing Lactobacillus cabbetts HY7601 as an active ingredient

Formulation examples of the pharmaceutical composition containing a novel Lactobacillus cabbetts HY7601 having an effective effect of lowering blood cholesterol and obesity of the present invention as an active ingredient, but the present invention is not intended to limit the present invention but only to be described in detail. It is.

Manufacture of tablets

Lyophilized powder 100mg, Lactobacillus cabbetts HY7601 of Example 1, 100mg cornstarch, 100mg lactose and 97mg polyvinylpyrrolidone were homogeneously mixed and granulated by wet granulation method and magnesium stearate 2 MG was added and mixed, and then one tablet was compressed to 400 mg.

Preparation of Capsules

Lyophilized powder 100mg, Lactobacillus cavities HY7601 of Example 1 100mg, corn starch 100mg, lactose 100mg, magnesium stearate 2mg thoroughly mixed in the hard gelatin capsules according to the manufacturing method of conventional capsules The capsule was prepared by filling.

<Example 3>

Preparation of fermented milk containing Lactobacillus cabbetts HY7601 as an active ingredient

Method for producing a fermented milk consisting of Lactobacillus culture medium and Lactobacillus cabbetts HY7601 having a blood cholesterol lowering and obesity inhibitory effect of the present invention and mixed fruit juice syrup are as follows.

First, the lactic acid bacteria culture medium was stirred at 95.36% by weight of crude milk and 4.6% by weight of skim milk powder (or mixed milk powder), and the specific gravity at 15 ° C was 1.0473 to 1.0475, the titratable acidity was 0.200 to 0.220%, and the pH was 6.65 to 6.70, 20 ° C. Brix ^o was mixed to be 16.3 ~ 16.5%. After mixing, it was UHT heat-treated (sterilized at 135 ° C for 2 seconds) and cooled to 40 ° C. Then, Streptococcus thermophilus and Lactobacillus (Valley laboratory, USA) were added to each of 0.02% by weight and incubated for 6 hours. Total lactic acid bacteria in the BCP medium was prepared by 1.0 × 10 ⁹ cfu / ㎖ or more, the titratable acidity is 0.89 ~ 0.91%, pH is 4.55 ~ 4.65.

Next, the mixed fruit syrup is 13% by weight liquid fructose, 5% by weight white sugar, 10.9% by weight mixed juice concentrate 56Brix ^o , 1.0% by weight pectin, 0.1% by weight fresh fruit mix essence and 70% by weight purified water at 30 ~ 35 ℃ After mixing by stirring, UHT heat treatment (sterilized for 2 seconds at 135 ℃) and then prepared by cooling.

Then, 69.5% by weight of the lactic acid bacteria culture medium and 0.1% by weight of the lyophilized powder including Lactobacillus cavities HY7601 of Example 1 and 30.4% by weight of the mixed fruit juice syrup were homogenized at 150 bar and then cooled to 10 ° C. or less. Fermented milk containing Lactobacillus cabbetts HY7601 having blood cholesterol lowering and obesity inhibitory efficacy was prepared.

<Example 4>

Preparation of Functional Drinks Containing Lactobacillus Cabbetts HY7601 as Active Ingredient

Method for producing a functional beverage consisting of Lactobacillus Corbettus HY7601 and mixed juice syrup having a blood cholesterol lowering and obesity inhibitory effect is as follows.

First, mixed fruit syrup is 13% by weight of liquid fructose, 2.5% by weight of white sugar, 2.5% by weight of brown sugar, 56% by weight of mixed juice concentrate 56Brix ^o , 1.0% by weight pectin, 0.1% by weight of fresh fruit mix essence and 70% by weight of purified water After mixing by stirring at 30 ~ 35 ℃ UHT heat treatment (sterilized for 2 seconds at 135 ℃) was prepared by cooling.

And a mixture of 30.4% by weight of the mixed juice syrup prepared by the above method, 0.1% by weight of lyophilized powder including Lactobacillus cavities HY7601 of Example 1 and 69.5% by weight of the remaining purified water were homogenized at 150 bar to 10 ° C or less. After cooling, the resultant was packaged in a small packaging container such as a glass bottle or a plastic bottle to prepare a functional beverage containing Lactobacillus corpus HY7601 as an active ingredient having blood cholesterol lowering and anti-obesity efficacy.

<Example 5>

Preparation of dietary supplement containing Lactobacillus cabbetts HY7601 as an active ingredient

Lactobacillus HY7601 lactobacillus HY7601 of Example 1 in the lyophilized powder (vitamin B1, B2, B5, B6, E and acetate esters, nicotinic acid amide) and oligosaccharides in the lactose of Example 1 10 parts by weight based on 100 parts by weight of the lyophilized powder including Bacillus cathetus HY7601 was added and mixed in a high speed rotary mixer. 10 parts by weight of sterile purified water was added and mixed with respect to 100 parts by weight of the mixture, and molded into granules having a diameter of 1 to 2 mm. The molded granules were dried in a vacuum dryer at 40 to 50 ° C., and then uniformly prepared granules were passed through 12 to 14 mesh. The granules prepared as described above were extruded by appropriate amounts into tablets or powders or filled into hard capsules to produce hard capsule products.

<Test Example 1>

Determination of ability to increase SREBP-2 activity by Lactobacillus cavities HY7601

1-1. pGL3-SRE Luciferase Plasmid Construction

A sterol-response element (SRE), which is a site where SREBP-2 binds to genomic DNA and initiates transcription, was inserted into pGL3 luciferase plasmid (Promega, E1751) to prepare pGL3-SRE luciferase plasmid. The site containing SRE is selected from -488 to +37 of the HMG-CoA synthase 1 gene (Homo sapiens 3 hydroxy 3 methylglutaryl Coenzyme A synthase 1) and the polymerase chain reaction (PCR). Amplified by Genomic DNA of HeLa cells was used as a template for PCR, and primers were designed as shown in Table 2. The underlined portion of the primer base sequence represents the restriction enzyme base sequence.

The amplified SRE site was inserted into the XhoI / HindIII restriction enzyme site in the pGL3 luciferase plasmid to obtain the pGL3-SRE luciferase plasmid, and finally the sequencing was performed by Solgent to confirm that the insertion was correct. . In FIG. 2, the nucleotide sequence into which the part marked in red is inserted is inserted.

1-2. HepG2 cell culture

HepG2 cells were obtained from Korea Cell Line Bank and cultured at 37% with 5% CO ₂ using DMEM medium containing 10% fetal bovine serum and L-glutamine (glutamine). And they were passaged two or three times a week.

1-3. Transfection

Transfection of the pGL3-SRE luciferase plasmid to HepG2 cells results in expression of the luciferase luminescent gene linked behind the SRE site as SREBP-2 present in the cell binds to the SRE site on the plasmid to initiate transcription. . This emission intensity was measured by a detector (Synergy 2, BIO-TEK) to determine the activity of SREBP-2.

For transfection, the mass of pGL3-SRE luciferase plasmid was first mass-produced using EndoFree plasmid Maxi Kit (Qiagen, 12362). Dilute 24 μg of pGL3-SRE luciferase plasmid in 1.2 mL of Opti-MEM I Reduced serum medium on a 75 cm 2 flask and 48 μL of Lipofectamine 2000 (Invitrogen, 11668-027) in 1.2 mL of the same medium. After dilution, the two dilutions were mixed and left for 20 minutes. HepG2 cells grown at about 70-80% in 75 cm 2 flasks were separated with trypsin and incubated with the mixture at 37 ° C. in a 5% CO ₂ cell incubator.

1-4. Determination of ability to increase SREBP-2 activity by Lactobacillus catheter HY7601 in HepG2 cells

Prior to measuring the ability to increase SREBP-2 activity by Lactobacillus cavities HY7601, it was confirmed whether the previously prepared pGL3-SRE luciferase plasmid was suitable for measuring the activity of SREBP-2.

The results are shown in Fig.

In Figure 3, A is non-treated, B is 25-hydroxycholesterol (25-Hydroxycholesterol; Sigma, H1015) 1 µg / ml and cholesterol (Sigma C8667) 10 µg / ml, C is palmitoylglycerophospho Choline (Rac-1-Palmitoyl-glycero-3-phosphocholine, hereinafter referred to as 'LPC'; Fluka, 76186) 20 μM, D was treated with U18666A (Sigma, U3633) 2 μg / ml, B, C, D represents the relative pGL3-SRE luciferase intensity of each.

As can be seen in Figure 3, the case of B indicates that the amount of intracellular cholesterol is increased by the reagents as a result of which the activity of SREBP-2 is reduced, indicating that pGL3-SRE luciferase intensity is reduced, C is The concentration of pGL3-SRE luciferase increased because the activity of SREBP-2 increased as the amount of intracellular cholesterol decreased as a result of the excretion of intracellular cholesterol by the reagent, and D represents cholesterol by the reagent. As the synthesis was inhibited, the amount of intracellular cholesterol decreased, indicating that the activity of SREBP-2 was increased, indicating that pGL3-SRE luciferase intensity was increased. Taken together, it was concluded that the pGL3-SRE luciferase plasmid was suitable for measuring the activity of SREBP-2.

As described above, since the pGL3-SRE luciferase plasmid was suitable for measuring the activity of SREBP-2, the ability to increase SREBP-2 activity by Lactobacillus corpus HY7601 was measured.

First, the domestically prepared kimchi in MRS liquid medium containing 0.02% sodium azide (MRS) liquid medium and incubated for 24 hours at 37 ℃, take the culture medium using 10μl platinum yi again Plated in agar plate agar containing 0.02% sodium azide and incubated for 48 hours at 37%. As a result of measuring the pGL3-SRE luciferase intensity change after treatment of various lactic acid bacteria in the thus-formed HepG2 cells, it was found that the pGL3-SRE luciferase intensity was increased by the Lactobacillus catheterus HY7601 of the present invention.

The results are shown in FIG.

In FIG. 4, A is treated with none, B is 20 μM of LPC, and C is a group treated with 10 ⁴ lactobacillus catheterus H7601 (same as the number of HepG2 cells), and the relative pGL3 of B and C with respect to A is shown. SRE Luciferase intensity.

As can be seen in FIG. 4, it was found that the pGL3-SRE luciferase intensity was increased by 30% or more compared to A by Lactobacillus catheterus HY7601. As a result, it was found that the amount of cholesterol in HepG2 cells was reduced by Lactobacillus catheterus HY7601.

<Test Example 2>

Determination of Cholesterol Lowering and Obesity Inhibition by Lactobacillus catheter HY7601

2-1. Obesity Inhibition

The experimental animals were used after adapting to a high-fat diet for 1 week by purchasing three-week-old male mice from ICR. Mice in all experimental groups were randomly assigned to 10 mice. As shown in Table 3, the experimental group was composed of three groups of the general diet group, high fat diet group, Lactobacillus cabbetts HY7601 group (high fat diet + Lactobacillus cabbetts HY7601), and the general diet and high fat diet were D12450B respectively from Research diets. (10% fat) and D12451 (45% fat) were used and used. Lactobacillus catheter HY7601 strain was inoculated in MS liquid medium and incubated at 37 ° C. for 20 hours. The cultured cells were centrifuged at 3,000 rpm at 4 ° C. for 10 minutes to mix with the diet and administered to mice.

The diet was fed for a total of eight weeks, and body weight and feed intake were measured twice a week.

The results are shown in FIG. 5 and Table 4.

As can be seen in Figure 5, the group ingesting Lactobacillus corbetters HY7601 was found that the weight gain was significantly suppressed compared to the group ingested only a high fat diet. In addition, as shown in Table 4, the weight gain of the 8-week weight, Lactobacillus cavities HY7601 group is 9.42 ± 1.65, high-fat diet group is 16.58 ± 3.94, the weight gain is increased by Lactobacillus Corbetts HY7601 It was confirmed that approximately 45% inhibition.

2-2. Blood Cholesterol and Triglyceride Measurement

In order to measure blood biochemical markers, the mice of each group were fasted for 12 hours, and blood samples were separated from the plasma. Blood concentrations of cholesterol and triglycerides were measured using a kit purchased from Asan Pharmaceutical.

An enzyme reagent was prepared by mixing one bottle of enzyme reagent and one bottle of buffer solution, and the reaction was compared by mixing 1.5 ml of enzyme solution with 10 μl of serum or 10 μl of standard solution. After reacting for 5 minutes at 37 ℃ absorbance was measured at 500nm. The cholesterol and triglyceride concentrations of the sample were calculated as follows.

Concentration of sample (mg / dl) = absorbance of sample / absorbance of standard solution x concentration of standard solution

The results are shown in Table 5.

As can be seen in Table 5, the blood cholesterol and triglyceride concentrations of the Lactobacillus catheterus HY7601 group was found to be significantly reduced compared to the high-fat diet only group (high-fat diet group). The cholesterol decreased by 17% and triglyceride by 32%.

(* P <0.05, ** P <0.01)

<Test Example 3>

Significant difference in marker gene expression by Lactobacillus catheter HY7601 in mouse liver tissue

Expression differences of SREBP-2, LDL-receptor, and GAPDH (house-keeping gene for correcting experimental results) genes of liver tissues extracted from the mouse of Test Example 2 were measured by real-time PCR. First, RNA is extracted from liver tissue using RNA queous kit (Ambion, AM1912), and complementary DNA ('cDNA') is complementary to RNA using High Capacity RNA-to-cDNA kit (Applied Biosystems, 4387406). Secured). Real-time RCR (Applied Biosystems, 7500 Real time PCR) was performed using Taqman probes (Taqman probes, purchased from Applied Biosystems) and the cDNA, as shown in Table 6 below.

The results are shown in FIG.

As can be seen in Figure 6 SREBP-2 and LDL-receptor expression was observed lower than expected in the high-fat diet group (A) than the normal diet group (C). However, in the Lactobacillus catheterus HY7601 group (B), the expression level of these genes was observed to recover again. In other words, the LDL-receptor expression of the cell membrane is increased by Lactobacillus catheter HY7601, which can be interpreted as a decrease in the amount of cholesterol in the blood due to increased cholesterol inflow.

1 is a diagram showing the results of a sugar fermentation experiment of Lactobacillus corbettus HY7601 using api 50 CH kit of Biomerieux.

Figure 2 is a diagram showing the upper portion of the HMG-CoA synthase 1 gene -488 ~ +37 inserted in the pGL3-SRE luciferase plasmid.

Figure 3 is a graph showing the results of measuring pGL3-SRE luciferase intensity in HepG2 cells.

4 is a graph showing the results of measuring pGL3-SRE luciferase intensity by Lactobacillus catheter HY7601 in HepG2 cells.

5 is a graph showing the change in the average weight of the mice for 8 weeks.

6 is a graph illustrating the relative RNA amounts of SREBP-2 and LDL-receptor genes in mouse liver tissue using real-time PCR.

Claims (7)

Novel Lactobacillus curvatus HY7601 (Accession No .: KCTC 11456BP) with blood cholesterol lowering and obesity inhibition efficacy. The method of claim 1, Lactobacillus curvatus ( Lactobacillus curvatus ) HY7601 by increasing the amount of LDL-receptor expression of liver tissue cells to reduce the blood cholesterol by introducing excess blood cholesterol into the cells, characterized in that Lactobacillus curvatus ( Lactobacillus curvatus) ) HY7601. The method of claim 1, The Lactobacillus curvatus HY7601 is characterized by having a triglyceride-reducing and obesity inhibitory effect ( Lactobacillus curvatus ) HY7601. Lactobacillus curvatus of claim 1 ( Lactobacillus curvatus ) A pharmaceutical composition for lowering blood cholesterol and obesity, characterized in that it contains as an active ingredient. Lactobacillus curvatus of claim 1 ( Lactobacillus curvatus ) Fermented milk for lowering blood cholesterol and obesity, characterized in that it contains HY7601 as an active ingredient. Lactobacillus curvatus ( Lactobacillus curvatus ) HY7601 of claim 1 characterized in that the blood cholesterol lowering and anti-obesity beverages containing as an active ingredient. Lactobacillus curvatus ( Lactobacillus curvatus ) HY7601 of claim 1, characterized in that it contains a healthy functional food for lowering blood cholesterol and obesity.

Images